Temperature-triggered liquefication of hydrogels for intentional implant removal

The Diels-Alder (DA) reaction is one of the most studied thermoreversible reactions, suitable for the preparation of thermoreversible crosslinked materials. In this study, temperature- triggered liquefaction of DA hydrogels will be investigated. A DA model reaction is used to determine the retro- DA temperature of the two stereoisomers. A hydrogel based on furan-functionalized Poly-(N-(2-hydroxy-propyl) methacryl amide (PHPMA) and 4-arm-polyethylene glycol (PEG) with maleimide endgroups is rheologically investigated and liquefaction experiments are performed

Core-Shell-Nanoparticles with Superparamagnetic Properties for Novel Applications as Biomaterials

Due to the increasing average age of the population, the number of implants is also increasing and with it the number of explantations. Therefore, facilitated implant removal is of great interest. A nanocomposite consisting of superparamagnetic core-shell nanoparticles (CSNPs) and a synthetic polymer is supposed to be used as implant coating, aiming for a stimulus-inducible modification of the composite's rheological properties by hyperthermia. Here, the first steps following this concept, the synthesis and modification of the CSNP are reported. In this work magnetite nanoparticles build the core and are surrounded by a periodic mesoporous organisilica (PMO) shell. For this reason, the CSNP are referred to as magnetic PMO (mPMO) particles in the following

The ARIA-MASK-air® approach

Funding Information: The authors thank Ms Véronique Pretschner for submitting the paper. MASK‐air has been supported by Charité Universitätsmedizin Berlin, EU grants (EU Structural and Development Funds Languedoc Roussillon and Region PACA; POLLAR: EIT Health; Twinning: EIP on AHA; Twinning DHE: H2020; Catalyse: Horizon Europe) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis, Stallergènes‐Greer and Uriach. None for the study. ® Publisher Copyright: © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma.publishersversionpublishe

Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis.info:eu-repo/semantics/publishedVersio

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases

Temperature-triggered liquefication of hydrogels for intentional implant removal

The Diels-Alder (DA) reaction is one of the most studied thermoreversible reactions, suitable for the preparation of thermoreversible crosslinked materials. In this study, temperature- triggered liquefaction of DA hydrogels will be investigated. A DA model reaction is used to determine the retro- DA temperature of the two stereoisomers. A hydrogel based on furan-functionalized Poly-(N-(2-hydroxy-propyl) methacryl amide (PHPMA) and 4-arm-polyethylene glycol (PEG) with maleimide endgroups is rheologically investigated and liquefaction experiments are performed

Core-Shell-Nanoparticles with Superparamagnetic Properties for Novel Applications as Biomaterials

Due to the increasing average age of the population, the number of implants is also increasing and with it the number of explantations. Therefore, facilitated implant removal is of great interest. A nanocomposite consisting of superparamagnetic core-shell nanoparticles (CSNPs) and a synthetic polymer is supposed to be used as implant coating, aiming for a stimulus-inducible modification of the composite’s rheological properties by hyperthermia. Here, the first steps following this concept, the synthesis and modification of the CSNP are reported. In this work magnetite nanoparticles build the core and are surrounded by a periodic mesoporous organisilica (PMO) shell. For this reason, the CSNP are referred to as magnetic PMO (mPMO) particles in the following

A Deep Learning Vision Transformer using Majority Voting Ensemble for Nematode Classification with Test Time Augmentation Technique

International audienc

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper

BackgroundChronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes. MethodsThe current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet. ResultsBased on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic. ConclusionIntranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.Peer reviewe